-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4444 A Phase II Prospective Study Evaluating an L-Asparaginase Regimen, Simple, in Newly Diagnosed Extranodal NK/T Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Monday, December 9, 2024, 6:00 PM-8:00 PM

Thomas S Chan, FRCP, MBBS, MRCP1*, Yok-Lam Kwong, MD2*, Eric Tse, PhD, MBBS3, Tony Kwun Yat Wu, BSc, MBBS, MRCP, FHKCP, FHKAM3* and Cheong Ngai4*

1Queen Mary Hospital, Hong Kong, Hong Kong
2Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
3Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
4Queen Mary Hospital, Hong Kong, HKG

Background:

Extranodal NK/T-cell lymphoma (ENKTL) is a rare and aggressive subtype of mature T- and NK-cell lymphoma, characterized by resistance to conventional anthracycline-containing chemotherapy owing to high levels of P-glycoprotein expression in neoplastic cells. Non-anthracycline, non-P-glycoprotein dependent regimens, such as SMILE, have shown remarkable efficacy. However, the SMILE regimen is associated with significant toxicities associated with treatment related mortalities. A regimen that is effective and less toxic is needed, particularly for older patients with poor tolerance to chemotherapy.

Methods:

This prospective phase II study enrolled consecutive patients aged ≥ 16 years with histologically confirmed newly-diagnosed ENKTL from January 2013 to September 2023. Patients were excluded if they had central nervous system involvement or an expected survival of less than 3 months. The trial was approved by institutional ethics committee (ClinicalTrials.gov I.D.: NCT03071822).

The SIMPLE regimen consisted of cisplatin 25 mg/m2 on days 1-3, gemcitabine 750 mg/m2 on days 1 and 15, ifosfamide 1200 mg/m2 on days 2-4, dexamethasone 40 mg on days 2-4, and L-asparaginase 6000 units/m2 on even days 8-20. Six cycles of treatment were given at 28-day intervals. For limited-stage disease, involved-field radiotherapy of 50 Gy was administered between cycles 3 and 4 of chemotherapy. Dose reductions of 25% were allowed for patients experiencing prolonged grade 4 hematological toxicities in the prior cycle, and up to 50% for those aged ≥ 65 years.

The primary endpoints were the overall response rate (ORR) and complete response rate (CR) stratified by stage I/II and stage III/IV disease. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and treatment-related toxicities (graded according to CTCAE v5.0). Statistical analyses were performed using IBM SPSS v23.0, with a significance level of p=0.05. Kaplan Meier method was used for survival analysis.

Results:

For the stage I/II disease cohort, 63 patients (male=39; female=24) at a median age of 55(29-85) years were enrolled. Of 62 evaluable patients, the best responses were: partial response (PR; N=4, 6.4%), CR (N=54, 87%), giving an ORR of 93.4%. At a median follow-up of 43 months, the median PFS and OS were not reached. The 3-year PFS and OS were 73.8% and 83%. The prognostic score for NK lymphoma, PINK-E, was significantly associated with PFS (3-year PFS for score 0: 94%; 1: 76.6%; and 2: 36%; p<0.01).

For the stage III/IV cohort, 37 patients (male=16; female=21) at a median age of 60 (16-78) years were enrolled. Of 35 evaluable patients, the ORR was 80% (CR: 65.7%; PR: 14.3%). With a median follow-up of 18 months, the 2-year PFS and OS were 30.5%. and 60.2%. Note that the relatively low 2-year PFS was due to censoring at the time of consolidation with either allogeneic hematopoietic stem cell transplantation (N=5) or anti-PD1 antibodies (N=11).

Hematologic toxicities included neutropenia (99%; grade 3/4: 95%), thrombocytopenia (100%; grade 3/4: 89%), and anemia (100%; grade 3/4: 28%). Important non-hematologic toxicities included mucositis (78%; grade 3/4: 4%) and elevated alanine aminotransferase (71%;grade 3/4: 4%). Anaphylaxis to L-asparaginase was reported in 4% (all grade 3). There was no treatment-related mortality.

Conclusion

The SIMPLE regimen is a highly effective regimen with tolerable toxicity. However, the results for stage III/IV disease require further improvement.

Disclosures: Chan: Novartis: Other: Travel support; Takeda: Other: Travel support. Kwong: Amgen: Consultancy; Astellas: Consultancy; GSK: Honoraria; Bayer: Consultancy; BeiGene: Consultancy; BMS: Consultancy, Research Funding; Celgene: Consultancy; Janssen: Consultancy; Merck: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Roche: Consultancy; Takeda: Consultancy.

*signifies non-member of ASH